Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJules Bordet Institute
About this trial
This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein).
The aim of the study is to assess the accuracy of Ga68-FAPI-46 PET/CT for preoperative assessment of peritoneal carcinomatosis in colorectal and ovarian cancer.
Eligibility criteria
Qualifiers
Histologically proven colorectal and ovarian cancer.
Known or suspected peritoneal metastases from the tumour of origin.
Scheduled for peritoneal complete cytoreductive surgery with curative intent with or without neoadjuvant chemotherapy.
ECOG (Eastern Cooperative Oncology Group) Performance status ≤2.
Disqualifiers
Non-resectable extra-abdominal metastasis and/or >3 hepatic metastases on standard work-up
Known chronic inflammatory conditions including the intestinal system (eg. inflammatory bowel disease, Crohn's disease)
Pregnant and lactating women
Previous or concurrent malignancy diagnosed within the last 3 years except adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell skin cancer.
Trial design
Treatments tested in this trial
- FAPI PET/CT
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov